全部文献期刊会议图书|学者科研项目
中外文文献  中文文献  外文文献
作者:Chun-Ling Dong , Fang-Chun Guo , Jie Xue
来源:[J].Medicinal Chemistry Research(IF 1.612), 2017, Vol.26 (9), pp.1926-1934Springer
摘要:... A gatekeeper mutation (T768I) of HER3 abrogates bosutinib binding to the ATP-binding site. This mechanism remains unresolved. Here, we performed molecular dynamic simulations and molecular mechanics/generalized born surface area binding free energy calculations to provide ins...
作者:Poe-Hirr Hsyu , Diane R. Mould , Richat Abbas ...
来源:[J].Drug Metabolism and Pharmacokinetics(IF 2.071), 2014, Vol.29 (6), pp.441-448Elsevier
摘要:Summary:(#br)Bosutinib is an orally active, competitive inhibitor of Src/Abl tyrosine kinases. A population pharmacokinetic model was developed using data pooled from 3 studies of patients ( n = 870) with solid tumors or Philadelphia chromosome-positive leukemia. Patients (ag...
作者:Katya Uzunova , Elena Filipova , Toni Vekov
来源:[J].Journal of Cancer Research and Therapeutics(IF 0.761), 2018, Vol.14 (5), pp.909-915Wolters Kluwer
摘要:Aim of Study: This review aims to highlight that bosutinib represents a valuable alternative for patients already treated unsuccessfully with one or more other tyrosine kinase inhibitors (TKIs). Chronic myelogenous leukemia (CML) is a myeloproliferative neoplasm associated with a...
作者:Naoto Takahashi , Chiaki Nakaseko , Yukio Kobayashi ...
来源:[J].International Journal of Hematology(IF 1.681), 2017, Vol.106 (3), pp.398-410Springer
摘要:This long-term follow-up of a completed phase 1/2 study assessed the safety and efficacy of bosutinib in Japanese Philadelphia chromosome-positive, chronic phase (CP) or advanced phase (ADV) chronic myeloid leukemia patients who were resistant/refractory or intolerant to prio...
作者:Suma K. Pawar , Roopa S. Naik , J. Seetharamappa
来源:[J].Analytical and Bioanalytical Chemistry(IF 3.659), 2017, Vol.409 (27), pp.6325-6335Springer
摘要:Bosutinib (BST) and imatinib mesylate (IMT) are tyrosine kinase inhibitors (TKIs). In view of the importance of these inhibitors in cancer treatment, we investigated the mechanism of interaction between BST/IMT and bovine serum albumin (BSA) using various spectroscopic and molec...
作者:Xiao Jia Yin , Guan Hong Xu , Xu Sun ...
来源:[J].Molecules(IF 2.428), 2010, Vol.15 (6), pp.4261DOAJ
摘要:This paper reports a novel synthesis of bosutinib starting from 3-methoxy-4-hydroxybenzoic acid. The process starts with esterification of the starting material, followed by alkylation, nitration, reduction, cyclization, chlorination and two successive amination reactions. The in...
作者:Keller-von Amsberg G , Koschmieder S
来源:[J].OncoTargets and Therapy(IF 2.073), 2013, Vol.2013 (default), pp.99-106DOAJ
摘要:Gunhild Keller-von Amsberg,1 Steffen Koschmieder21Department of Hematology and Oncology, University Cancer Center Hamburg, University Hospital Hamburg Eppendorf, 2Department of Medicine (Hematology, Oncology, and Stem Cell Transplantation), University Medical Center of Aachen and RWTH Aachen University, Aachen, GermanyAbstract: Bosutinib...
作者:Richat Abbas , Cathie Leister , Myriam El Gaaloul ...
来源:[J].Clinical Therapeutics(IF 2.23), 2012, Vol.34 (9), pp.2011-2019.e1Elsevier
摘要:Abstract(#br)Background(#br)Bosutinib (SKI-606) is an orally bioavailable, competitive tyrosine kinase inhibitor that selectively targets both Src and Abl tyrosine kinases. Bosutinib is metabolized primarily through the cytochrome P450 3A4 pathway. Inhibition of bosutinib meta...
作者:Poe-Hirr Hsyu , Daniela Soriano Pignataro , Kyle Matschke
来源:[J].European Journal of Clinical Pharmacology(IF 2.741), 2017, Vol.73 (1), pp.49-56Springer
摘要:Abstract(#br) Purpose(#br)Bosutinib is an oral, dual Src and Abl tyrosine kinase inhibitor (TKI) approved for the treatment of Philadelphia chromosome—positive chronic myeloid leukemia resistant or intolerant to prior TKI therapy. Bosutinib is primarily metabolized by cytoch...
作者:Maiko Abumiya , Akiko Mita , Saori Takahashi ...
来源:[J].Medical Oncology(IF 2.147), 2018, Vol.35 (6), pp.1-7Springer
摘要:Abstract(#br)We investigated the effects of polymorphisms in NR1I2 (7635A>G, 8055C>T), CYP3A4 (20230G>A), ABCB1 (1199G>A, 1236C>T, 2677G>T/A, 3435C>T), and ABCG2 (421C>A) on the mean plasma trough concentrations ( C 0 ) of bosutinib at the steady-state in 30 Japanese patients ...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×